Baidu
map

Ann Intern Med:连续服用低剂量阿司匹林和NSAIDs均可降低大肠癌的风险

2015-09-01 崔倩 译 MedSci原创

最近一项综合性研究的结论是,需要更多的研究以使用阿司匹林确定预防癌症的最佳方法。该研究的目的是评估低剂量阿司匹林或其它非甾体类抗炎药(NSAIDs)和结直肠癌风险的之间的关联。该项以人群为基础的,病例对照研究在丹麦北部进行。该研究的患者在1994年和2011年之间第一次被确诊为大肠癌,患者来自于丹麦北部。对照参与者是由风险设置抽样选择出来的。药物的使用,合并症和结肠镜检查的历史数据来自于处方和患者

最近一项综合性研究的结论是,需要更多的研究以使用阿司匹林确定预防癌症的最佳方法。该研究的目的是评估低剂量阿司匹林或其它非甾体类抗炎药(NSAIDs)和结直肠癌风险的之间的关联。

该项以人群为基础的病例对照研究在丹麦北部进行。该研究的患者在1994年和2011年之间第一次被确诊为大肠癌,且都来自于丹麦北部。对照参与者是由风险设置抽样选择出来的。

药物的使用、合并症和结肠镜检查的历史数据来自于处方和患者登记记录。低剂量阿司匹林(75〜150mg)的使用和非阿司匹林NSAIDs是根据类型、估计剂量、持续时间和使用的一致性定义的。

共有10280例患者和102800名对照参与者,与曾经使用(≥2处方)低剂量阿司匹林和非阿司匹林的NSAIDs相关的大肠癌调整后的比值比(OR)分别是1.03(95%Cl,0.98〜1.09)和0.94(Cl,0.90〜0.98)。低剂量阿司匹林连续长期使用(≥5年)与大肠癌风险降低27%相关(OR,0.73[Cl,0.54〜0.99]),而长期累积使用的整体OR(连续或不连续)接近统一。非阿司匹林NSAIDs使用可以大幅度减少结直肠癌风险,特别是高环氧合酶-2选择性药剂的长期,高强度使用(平均限定日剂量≥0.3)(OR0.57[Cl,0.44〜0.74])。

该研究的局限性在于数据不适用于那些通过柜台购买高剂量阿司匹林和低剂量的布洛芬或NSAIDs的剂量方案,而且作者无法通过一些风险因素调整做几个比较。

长期、连续服用低剂量阿司匹林和长期服用非阿司匹林的NSAIDs药物均可降低大肠癌的危险。连续使用低剂量阿司匹林的患者只占低剂量阿司匹林使用者很小的比例。

原始出处:

Søren Friis, Anders H. Riis,Rune Erichsen,et al.Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drug Use and Colorectal Cancer Risk,Ann Intern Med,2015.9.1

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1793577, encodeId=86b51e93577b9, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Tue Jun 21 09:35:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007446, encodeId=9efc200e44677, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Fri Apr 01 23:35:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033828, encodeId=69c52033828a0, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Fri Sep 04 10:35:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36383, encodeId=d9c136383c9, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150904/IMG55E8DB68F05883098.jpg, createdBy=e00a1631985, createdName=fengzhigu, createdTime=Fri Sep 04 07:54:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323169, encodeId=7d8a13231693d, content=<a href='/topic/show?id=ee9b13065da' target=_blank style='color:#2F92EE;'>#NSAIDs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13065, encryptionId=ee9b13065da, topicName=NSAIDs)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365619, encodeId=83c4136561931, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413631, encodeId=2cc5141363130, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80342986042, createdName=amyloid, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480415, encodeId=1471148041509, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606598, encodeId=977e160659857, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36357, encodeId=d74a3635e2d, content=很有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a25c1635554, createdName=byzh1990, createdTime=Thu Sep 03 02:34:00 CST 2015, time=2015-09-03, status=1, ipAttribution=)]
    2016-06-21 d830372
  2. [GetPortalCommentsPageByObjectIdResponse(id=1793577, encodeId=86b51e93577b9, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Tue Jun 21 09:35:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007446, encodeId=9efc200e44677, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Fri Apr 01 23:35:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033828, encodeId=69c52033828a0, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Fri Sep 04 10:35:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36383, encodeId=d9c136383c9, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150904/IMG55E8DB68F05883098.jpg, createdBy=e00a1631985, createdName=fengzhigu, createdTime=Fri Sep 04 07:54:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323169, encodeId=7d8a13231693d, content=<a href='/topic/show?id=ee9b13065da' target=_blank style='color:#2F92EE;'>#NSAIDs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13065, encryptionId=ee9b13065da, topicName=NSAIDs)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365619, encodeId=83c4136561931, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413631, encodeId=2cc5141363130, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80342986042, createdName=amyloid, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480415, encodeId=1471148041509, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606598, encodeId=977e160659857, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36357, encodeId=d74a3635e2d, content=很有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a25c1635554, createdName=byzh1990, createdTime=Thu Sep 03 02:34:00 CST 2015, time=2015-09-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1793577, encodeId=86b51e93577b9, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Tue Jun 21 09:35:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007446, encodeId=9efc200e44677, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Fri Apr 01 23:35:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033828, encodeId=69c52033828a0, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Fri Sep 04 10:35:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36383, encodeId=d9c136383c9, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150904/IMG55E8DB68F05883098.jpg, createdBy=e00a1631985, createdName=fengzhigu, createdTime=Fri Sep 04 07:54:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323169, encodeId=7d8a13231693d, content=<a href='/topic/show?id=ee9b13065da' target=_blank style='color:#2F92EE;'>#NSAIDs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13065, encryptionId=ee9b13065da, topicName=NSAIDs)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365619, encodeId=83c4136561931, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413631, encodeId=2cc5141363130, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80342986042, createdName=amyloid, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480415, encodeId=1471148041509, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606598, encodeId=977e160659857, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36357, encodeId=d74a3635e2d, content=很有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a25c1635554, createdName=byzh1990, createdTime=Thu Sep 03 02:34:00 CST 2015, time=2015-09-03, status=1, ipAttribution=)]
    2015-09-04 wjywjy
  4. [GetPortalCommentsPageByObjectIdResponse(id=1793577, encodeId=86b51e93577b9, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Tue Jun 21 09:35:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007446, encodeId=9efc200e44677, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Fri Apr 01 23:35:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033828, encodeId=69c52033828a0, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Fri Sep 04 10:35:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36383, encodeId=d9c136383c9, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150904/IMG55E8DB68F05883098.jpg, createdBy=e00a1631985, createdName=fengzhigu, createdTime=Fri Sep 04 07:54:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323169, encodeId=7d8a13231693d, content=<a href='/topic/show?id=ee9b13065da' target=_blank style='color:#2F92EE;'>#NSAIDs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13065, encryptionId=ee9b13065da, topicName=NSAIDs)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365619, encodeId=83c4136561931, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413631, encodeId=2cc5141363130, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80342986042, createdName=amyloid, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480415, encodeId=1471148041509, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606598, encodeId=977e160659857, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36357, encodeId=d74a3635e2d, content=很有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a25c1635554, createdName=byzh1990, createdTime=Thu Sep 03 02:34:00 CST 2015, time=2015-09-03, status=1, ipAttribution=)]
    2015-09-04 fengzhigu

    有意思

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1793577, encodeId=86b51e93577b9, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Tue Jun 21 09:35:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007446, encodeId=9efc200e44677, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Fri Apr 01 23:35:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033828, encodeId=69c52033828a0, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Fri Sep 04 10:35:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36383, encodeId=d9c136383c9, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150904/IMG55E8DB68F05883098.jpg, createdBy=e00a1631985, createdName=fengzhigu, createdTime=Fri Sep 04 07:54:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323169, encodeId=7d8a13231693d, content=<a href='/topic/show?id=ee9b13065da' target=_blank style='color:#2F92EE;'>#NSAIDs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13065, encryptionId=ee9b13065da, topicName=NSAIDs)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365619, encodeId=83c4136561931, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413631, encodeId=2cc5141363130, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80342986042, createdName=amyloid, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480415, encodeId=1471148041509, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606598, encodeId=977e160659857, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36357, encodeId=d74a3635e2d, content=很有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a25c1635554, createdName=byzh1990, createdTime=Thu Sep 03 02:34:00 CST 2015, time=2015-09-03, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1793577, encodeId=86b51e93577b9, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Tue Jun 21 09:35:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007446, encodeId=9efc200e44677, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Fri Apr 01 23:35:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033828, encodeId=69c52033828a0, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Fri Sep 04 10:35:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36383, encodeId=d9c136383c9, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150904/IMG55E8DB68F05883098.jpg, createdBy=e00a1631985, createdName=fengzhigu, createdTime=Fri Sep 04 07:54:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323169, encodeId=7d8a13231693d, content=<a href='/topic/show?id=ee9b13065da' target=_blank style='color:#2F92EE;'>#NSAIDs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13065, encryptionId=ee9b13065da, topicName=NSAIDs)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365619, encodeId=83c4136561931, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413631, encodeId=2cc5141363130, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80342986042, createdName=amyloid, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480415, encodeId=1471148041509, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606598, encodeId=977e160659857, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36357, encodeId=d74a3635e2d, content=很有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a25c1635554, createdName=byzh1990, createdTime=Thu Sep 03 02:34:00 CST 2015, time=2015-09-03, status=1, ipAttribution=)]
    2015-09-03 docwu2019
  7. [GetPortalCommentsPageByObjectIdResponse(id=1793577, encodeId=86b51e93577b9, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Tue Jun 21 09:35:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007446, encodeId=9efc200e44677, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Fri Apr 01 23:35:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033828, encodeId=69c52033828a0, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Fri Sep 04 10:35:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36383, encodeId=d9c136383c9, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150904/IMG55E8DB68F05883098.jpg, createdBy=e00a1631985, createdName=fengzhigu, createdTime=Fri Sep 04 07:54:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323169, encodeId=7d8a13231693d, content=<a href='/topic/show?id=ee9b13065da' target=_blank style='color:#2F92EE;'>#NSAIDs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13065, encryptionId=ee9b13065da, topicName=NSAIDs)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365619, encodeId=83c4136561931, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413631, encodeId=2cc5141363130, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80342986042, createdName=amyloid, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480415, encodeId=1471148041509, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606598, encodeId=977e160659857, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36357, encodeId=d74a3635e2d, content=很有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a25c1635554, createdName=byzh1990, createdTime=Thu Sep 03 02:34:00 CST 2015, time=2015-09-03, status=1, ipAttribution=)]
    2015-09-03 amyloid
  8. [GetPortalCommentsPageByObjectIdResponse(id=1793577, encodeId=86b51e93577b9, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Tue Jun 21 09:35:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007446, encodeId=9efc200e44677, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Fri Apr 01 23:35:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033828, encodeId=69c52033828a0, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Fri Sep 04 10:35:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36383, encodeId=d9c136383c9, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150904/IMG55E8DB68F05883098.jpg, createdBy=e00a1631985, createdName=fengzhigu, createdTime=Fri Sep 04 07:54:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323169, encodeId=7d8a13231693d, content=<a href='/topic/show?id=ee9b13065da' target=_blank style='color:#2F92EE;'>#NSAIDs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13065, encryptionId=ee9b13065da, topicName=NSAIDs)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365619, encodeId=83c4136561931, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413631, encodeId=2cc5141363130, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80342986042, createdName=amyloid, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480415, encodeId=1471148041509, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606598, encodeId=977e160659857, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36357, encodeId=d74a3635e2d, content=很有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a25c1635554, createdName=byzh1990, createdTime=Thu Sep 03 02:34:00 CST 2015, time=2015-09-03, status=1, ipAttribution=)]
    2015-09-03 heli0118
  9. [GetPortalCommentsPageByObjectIdResponse(id=1793577, encodeId=86b51e93577b9, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Tue Jun 21 09:35:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007446, encodeId=9efc200e44677, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Fri Apr 01 23:35:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033828, encodeId=69c52033828a0, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Fri Sep 04 10:35:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36383, encodeId=d9c136383c9, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150904/IMG55E8DB68F05883098.jpg, createdBy=e00a1631985, createdName=fengzhigu, createdTime=Fri Sep 04 07:54:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323169, encodeId=7d8a13231693d, content=<a href='/topic/show?id=ee9b13065da' target=_blank style='color:#2F92EE;'>#NSAIDs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13065, encryptionId=ee9b13065da, topicName=NSAIDs)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365619, encodeId=83c4136561931, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413631, encodeId=2cc5141363130, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80342986042, createdName=amyloid, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480415, encodeId=1471148041509, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606598, encodeId=977e160659857, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36357, encodeId=d74a3635e2d, content=很有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a25c1635554, createdName=byzh1990, createdTime=Thu Sep 03 02:34:00 CST 2015, time=2015-09-03, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1793577, encodeId=86b51e93577b9, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Tue Jun 21 09:35:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007446, encodeId=9efc200e44677, content=<a href='/topic/show?id=d4022616800' target=_blank style='color:#2F92EE;'>#低剂量阿司匹林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26168, encryptionId=d4022616800, topicName=低剂量阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9dd613, createdName=xxxx1049, createdTime=Fri Apr 01 23:35:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033828, encodeId=69c52033828a0, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Fri Sep 04 10:35:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36383, encodeId=d9c136383c9, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150904/IMG55E8DB68F05883098.jpg, createdBy=e00a1631985, createdName=fengzhigu, createdTime=Fri Sep 04 07:54:00 CST 2015, time=2015-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323169, encodeId=7d8a13231693d, content=<a href='/topic/show?id=ee9b13065da' target=_blank style='color:#2F92EE;'>#NSAIDs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13065, encryptionId=ee9b13065da, topicName=NSAIDs)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365619, encodeId=83c4136561931, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413631, encodeId=2cc5141363130, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80342986042, createdName=amyloid, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480415, encodeId=1471148041509, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606598, encodeId=977e160659857, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 03 06:35:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36357, encodeId=d74a3635e2d, content=很有意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a25c1635554, createdName=byzh1990, createdTime=Thu Sep 03 02:34:00 CST 2015, time=2015-09-03, status=1, ipAttribution=)]
    2015-09-03 byzh1990

    很有意义

    0

相关资讯

JCO:阿司匹林可预防结直肠癌发病风险

对于一般人群来说,肥胖是增加结直肠癌(CRC)的一个重要的危险因素,但结直肠癌风险的增加与林奇综合症患者(LS)的肥胖是否相关,目前还不清楚。本研究旨在评估癌症风险与林奇综合征患者(LS)超重或肥胖之间的关系。 通过CAPP2研究招募参与者,利用2x2因素设计,将患者随机分配,患者接收每天600mg阿司匹林或30g抗性淀粉或安慰剂,服用时长25个月,平均随访时间55.7个月。 在随访期间,其中

Ann Intern Med:阿司匹林、NSAIDS与降低患CRC风险相关

结直肠癌(CRC)是美国第三大最常见癌症,在男性中仅次于肺癌和前列腺癌,在女性中仅次于肺癌和乳腺癌。CRC是导致癌症患者死亡的第二大原因。约9/10的CRC患者年龄都超过50岁,且50岁以上的结肠肿瘤患者中有40%为良性肿瘤,约有2%发展为恶性肿瘤。但肿瘤进展十分缓慢,小剂量的阿司匹林和非甾体类抗炎药(NSAIDs)可以有效减缓肿瘤的进展并防止病情恶化。丹麦奥胡斯大学医院流行病学的一个研究团队发现

Stroke:急性缺血性脑卒中患者血小板的反应性随阿司匹林变化的临床意义

    目前研究已经发现冠状动脉疾病患者的血小板反应是岁时间而变化的。因此,研究人员试图评估在缺血性中风后的急性期血小板对阿司匹林应答的时间依赖性变化以及不同患者在急性缺血性中风中对阿司匹林的应答。    研究人员进行了一项单中心,前瞻性观察研究。急性阿司匹林反应单位(ARU)在服用阿司匹林3小时后进行测定,数值越高,表示血小板反应性增加。后续的ARU在连续

JCO:服用阿司匹林可降低肥胖Lynch综合征(结直肠癌)病人患癌风险

一项随机对照试验表明,日常服用阿司匹林的肥胖人群患癌风险降低。研究人员对937名患有林奇综合征(是一种呈常染色体显性遗传的家族性肿瘤,该病会明显增加患者的患癌风险,尤其是结肠癌和子宫癌)的患者进行了10年的调查随访。在这些患者中,研究人员发现,超重的患者患癌风险是正常体重的患者的2倍,但是若超重患者长期规律服用阿司匹林,则患癌风险降低,且这项研究发表在the Journal o

吃抗血栓药,你的基因“配合”吗?

为了控制疾病,如今许多人需要长期不间断地服用药物,最常见的莫过于降压药和抗血栓药(抗凝血药)。我的母亲每天服用降压药,已经超过二十年。而父亲七年前中风、今年又发生第二次中风,因此每天必须服用阿司匹林和华法林。然而,这两种广泛使用的抗凝血药物,在我父亲身上却效果不太明显。查阅过许多药物与遗传的相关文献后,我发现,还有其他患者曾遇过同样麻烦,而原因可能是“基因不配合”。阿司匹林(Aspirin):

Lab Invest:每日服用阿司匹林或可有效抑制乳腺癌的发展

近日,一项刊登在国际杂志Laboratory Investigation上的研究论文中,来自堪萨斯城退伍军人医疗中心的研究人员通过研究发现,每日服用一定的剂量的阿司匹林或可有效阻断乳腺癌的生长,此前研究显示阿司匹林或许对结肠癌、胃肠道癌、前列腺癌等其它癌症均有一定的抑制作用。Banerjee教授说道,在癌症治疗前期阶段一旦尽力去治疗患者,一般肿瘤都会有希望被有效遏制住,但由于癌症干细胞的存在,其往

Baidu
map
Baidu
map
Baidu
map